We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Whole-Blood Extracellular Vesicle Analysis Captures Molecular Signals Missed by Plasma Testing

By LabMedica International staff writers
Posted on 01 Sep 2026

Extracellular vesicles (EVs) carry proteins and lipids that reflect cell states and disease processes, but their analysis typically depends on plasma or serum. More...

This excludes signals originally present in whole blood and may limit clinical biomarker discovery. Meanwhile, biobanks worldwide store large numbers of whole-blood samples that remain underused for EV research. A new study shows that directly isolating circulating EVs from whole blood can recover complementary molecular information.

At IRBLleida’s +Pec Proteomics Research Group and the University of Lleida, together with Brock University and Newcastle University, researchers optimized the PRotein Organic Solvent PRecipitation (PROSPR) method for standardized enrichment of EVs directly from whole blood. PROSPR uses protein organic solvent precipitation to rapidly concentrate circulating vesicles. The workflow generated highly purified EV preparations while preserving vesicle morphology, membrane integrity, and stability.

Performance was validated using standard methodology in the field and then assessed with high-depth systems biology and multiomics analyses. The method was described as rapid and accessible, and it is compatible with standard laboratory equipment. These features are intended to facilitate use in biomedical and clinical research settings.

The main finding was that whole-blood-derived EVs contained coordinated platelet- and mitochondria-associated protein and lipid signatures that were not detected in corresponding plasma-derived EV fractions. Whole-blood EV analysis therefore captures complementary biological information that is lost when only plasma or serum is examined. Relying solely on plasma or serum can overlook molecular signals relevant to disease mechanisms and biomarker discovery.

The work, entitled “Optimized enrichment of circulating extracellular vesicles from whole blood samples using PROSPR,” was published in Extracellular Vesicles and Circulating Nucleic Acids on July 7, 2026. By enabling the analysis of previously underused archived whole-blood samples, PROSPR provides a practical strategy to unlock valuable national and international biobank collections. This approach may support deeper investigation of disease mechanisms and expand opportunities for discovering circulating biomarkers for early diagnosis, prognosis, and disease monitoring.

Related Links

IRBLleida


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
New
Gold Member
Serum Indices Control
Acusera Serum Indices Control
Automated Clinical Chemistry Analyzer
Envoy 500+
Platinum Member
Integrated Biochemical & Immunological System
Biolumi CX Solution X10+C10
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The AidaBREAST assay integrates multimodal data to provide patient-specific 10-year recurrence risk and individualized predictions of radiation therapy benefit (photo courtesy of PreludeDx)

Validated Test Predicts Recurrence Risk and Radiation Benefit in Early-Stage Breast Cancer

For women with early-stage invasive breast cancer who undergo breast-conserving surgery, clinicians must assess both the risk of locoregional recurrence and the potential benefit of adjuvant radiation therapy.... Read more

Microbiology

view channel
Image: Invasive aspergillosis (IA) is a potentially life-threatening infection caused by Aspergillus mold that primarily affects people with severely weakened immune systems. (Image Credit: Adobe Stock)

Rapid Urine Test Aids Diagnosis of Invasive Aspergillosis

Invasive aspergillosis is an uncommon mold infection in the general population but can pose serious risks for people with weakened immune defenses. Diagnosis can be difficult because existing approaches... Read more

Technology

view channel
Image: The laser-based photoacoustic spectroscopy setup consists of a Mid-IR laser equipped with three QCL modules covering wavelengths from 5.6 μm to 12.9 μm, two silver coated mirrors (SCM), a dichroic mirror (DM) with a transmittance of 90%, a thermal power sensor head (PM) to monitor the output laser power, a mechanical chopper (MC) for frequency modulation and a CEPAS-detector with a self-designed swab holder (SH). (Credit: Graunke, T., Scholz, T., Pieniak, M. et al. Scientific Reports (2026). https://doi.org/10.1038/s41598-026-68298-9)

Laser-Based Swab Analysis Shows Promise for Detecting Disease-Linked Odor Patterns

Disease-related changes in volatile organic compounds can alter body odor, producing measurable patterns in exhaled breath and bodily fluids. Current analytical methods can be complex, time-consuming,... Read more

Industry

view channel
Image: Natera\'s MCED assay analyzes cell-free DNA in blood to screen for multiple cancers (Image Credit: Adobe Stock)

Multi-Cancer Screening Blood Test Gains FDA Breakthrough Designation

Natera Inc.’s (Austin, TX, USA) multi-cancer early detection (MCED) assay has received Breakthrough Device designation (BDD) from the U.S. Food and Drug Administration (FDA). The assay analyzes cell-free... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.